Home/Filings/4/0000882104-17-000022
4//SEC Filing

PDL BIOPHARMA, INC. 4

Accession 0000882104-17-000022

CIK 0000882104operating

Filed

Mar 6, 7:00 PM ET

Accepted

Mar 7, 8:19 PM ET

Size

4.9 KB

Accession

0000882104-17-000022

Insider Transaction Report

Form 4
Period: 2017-03-04
Stone Christopher Lewis
VP and General Counsel
Transactions
  • Award

    Common stock

    2017-03-04$2.04/sh+214,372$437,319448,746 total
Footnotes (1)
  • [F1]The restricted stock will vest, provided that the officer remains employed by the Company and certain performance goals are achieved, based upon the following schedule: 50% on December 2018; 16.66% on December 2019; 16.66% on December 2020; and 16.66% on December 2021.

Issuer

PDL BIOPHARMA, INC.

CIK 0000882104

Entity typeoperating
IncorporatedDE

Related Parties

1
  • filerCIK 0000882104

Filing Metadata

Form type
4
Filed
Mar 6, 7:00 PM ET
Accepted
Mar 7, 8:19 PM ET
Size
4.9 KB